This impactful clinical trial aimed to go beyond outlining disparities in outcomes; it took a proactive step toward addressing these gaps to foster equity in breast cancer care. Its findings show that research, when specifically tailored to underrepresented populations, yields positive results. In a study carried out by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), Black patients with early-stage breast cancer who received docetaxel chemotherapy every three weeks experienced fewer

Advancing Precision Medicine by Integrating Genomic, Transcriptomic, Proteomic, and Clinical Data While smoking remains the leading cause of lung cancer, a rising number of cases in non-smokers—particularly among women—has been documented. Roughly 80% of lung cancer patients who never smoked receive treatments targeting specific protein mutations, like those in the EGFR and ALK genes. For those without such mutations, however, treatment often involves chemotherapy, which typically produces